Evidence map›Paper›PMID 30603126›Full record

ArticleJournal of gastrointestinal oncology2018

Tailored treatment of patients with hepatocellular carcinoma with portal vein invasion: experience from a multidisciplinary hepatobiliary tumor program within a NCI comprehensive cancer center.

Sarah Walcott-Sapp, Scott Naugler, Jeong Youn Lim, Jesse Wagner, Susan L Orloff, Khashayar Farsad, Kenneth J Kolbeck, John Kaufman, Erin Maynard, C Kristian Enestvedt and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sarah Walcott-SappDivision of Surgical Oncology, Department of Surgery, Oregon Health and Science University, Portland, OR, USA.
Scott NauglerDivision of Gastroenterology, Department of Medicine, Oregon Health and Science University, Portland, OR, USA.
Jeong Youn LimDivision of Biostatistics, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Jesse WagnerDivision of Surgical Oncology, Department of Surgery, Oregon Health and Science University, Portland, OR, USA.
Susan L OrloffAbdominal Transplant Division, Department of Surgery, Oregon Health and Science University, Portland, OR, USA.
Khashayar FarsadCharles T. Dotter Department of Interventional Radiology, Oregon Health and Science University, Portland, OR, USA.
Kenneth J KolbeckCharles T. Dotter Department of Interventional Radiology, Oregon Health and Science University, Portland, OR, USA.
John KaufmanCharles T. Dotter Department of Interventional Radiology, Oregon Health and Science University, Portland, OR, USA.
Erin MaynardAbdominal Transplant Division, Department of Surgery, Oregon Health and Science University, Portland, OR, USA.
C Kristian EnestvedtAbdominal Transplant Division, Department of Surgery, Oregon Health and Science University, Portland, OR, USA.
Skye C MayoDivision of Surgical Oncology, Department of Surgery, Oregon Health and Science University, Portland, OR, USA.
Kevin G BillingsleyDivision of Surgical Oncology, Department of Surgery, Oregon Health and Science University, Portland, OR, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) with portal vein invasion (PVI) has a poor prognosis with limited treatment options. Intra-arterial brachytherapy (IAB) and transarterial chemoembolization (TACE) yield local control but risk accelerating liver dysfunction. The outcomes, survival, and safety of selective liver-directed treatment are reported.

methodsThirty-seven consecutive patients with HCC and PVI treated between 2009 and 2015 were reviewed from a prospectively collected database. Univariate analysis, Kaplan-Meier plots using the log-rank method, and multivariate analyses were performed. Statistical significance was defined as P<0.05. Overall survival was reported in months (median; 95% CI).

resultsMost patients (59%) had PVI identified at initial HCC diagnosis. The liver-directed therapy group (n=22) demonstrated a survival advantage versus the systemic/supportive care group (n=14) [23.6 (5.8, 30.9)

conclusionsIn HCC patients presenting with PVI, liver-directed therapy was safely performed in patients with limited venous involvement and preserved liver function. Liver-directed therapy extended survival for these patients indicated for palliative chemotherapy by traditional guidelines.

Indexed as

Hepatocellular carcinoma (HCC)portal vein invasion (PVI)portal vein tumor thrombustransarterial chemoembolization (TACE)transarterial radioembolization

Identifiers

PMID30603126
PMCPMC6286927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.